Vanda Pharmaceuticals, Inc. (VNDA)
5.76
-0.34
(-5.57%)
USD |
NASDAQ |
Feb 20, 16:00
8.30
+2.54
(+44.10%)
After-Hours: 20:00
Vanda Pharmaceuticals SG&A Expense (Quarterly) : 62.98M for Dec. 31, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Eli Lilly & Co. | 3.132B |
| Axsome Therapeutics, Inc. | 150.24M |
| AnaptysBio, Inc. | 10.21M |
| SELLAS Life Sciences Group, Inc. | 2.867M |
| Protagenic Therapeutics, Inc. | 0.1599M |